Alliancebernstein L.P. Outlook Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.22 - $0.66 $3,839 - $11,517	-17,450 Reduced 16.16%	90,530 $35,000
Q3 2023 Nov 14, 2023	SELL	$0.2 - $1.78 $2,286 - $20,345	-11,430 Reduced 9.57%	107,980 $23,000
Q2 2023 Aug 15, 2023	BUY	$1.02 - $1.89 $77,020 - $142,713	75,510 Added 172.0%	119,410 $207,000
Q4 2022 Feb 14, 2023	BUY	$0.87 - $1.33 $9,222 - $14,098	10,600 Added 31.83%	43,900 $47,000
Q3 2022 Nov 15, 2022	BUY	$1.02 - $1.26 $5,100 - $6,300	5,000 Added 17.67%	33,300 $41,000
Q2 2022 Aug 15, 2022	BUY	$0.91 - $2.01 $25,753 - $56,882	28,300 New	28,300 $29,000
Q3 2021 Nov 10, 2021	SELL	$2.12 - $2.76 $36,040 - $46,920	-17,000 Closed	0 $0
Q2 2021 Jul 30, 2021	BUY	$1.78 - $2.76 $30,260 - $46,920	17,000 New	17,000 $42,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $486M
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.